274 related articles for article (PubMed ID: 27742065)
1. Current strategies to create tailored and risk-adapted therapies for CLL patients.
Cramer P; Eichhorst B; Reinhardt HC; Hallek M
Best Pract Res Clin Haematol; 2016 Mar; 29(1):111-121. PubMed ID: 27742065
[TBL] [Abstract][Full Text] [Related]
2. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
[TBL] [Abstract][Full Text] [Related]
3. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
4. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
6. Possible novel agents in marginal zone lymphoma.
Zinzani PL; Broccoli A
Best Pract Res Clin Haematol; 2017; 30(1-2):149-157. PubMed ID: 28288710
[TBL] [Abstract][Full Text] [Related]
7. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Cramer P; Tausch E; von Tresckow J; Giza A; Robrecht S; Schneider C; Fürstenau M; Langerbeins P; Al-Sawaf O; Pelzer BW; Fink AM; Fischer K; Wendtner CM; Eichhorst B; Kneba M; Stilgenbauer S; Hallek M
Blood; 2021 Nov; 138(19):1805-1816. PubMed ID: 34086865
[TBL] [Abstract][Full Text] [Related]
8. How should we sequence and combine novel therapies in CLL?
Davids MS
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):346-353. PubMed ID: 29222277
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.
Goede V; Hallek M
Drugs Aging; 2015 Nov; 32(11):877-86. PubMed ID: 26446155
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
11. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
[TBL] [Abstract][Full Text] [Related]
12. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Molica S
Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
[TBL] [Abstract][Full Text] [Related]
13. Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Woyach JA
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):476-481. PubMed ID: 31808904
[TBL] [Abstract][Full Text] [Related]
14. [Chronic lymphocytic leukemia: current standards and novel approaches].
Tausch E; Stilgenbauer S
Internist (Berl); 2014 Dec; 55(12):1400, 1402-4, 1406-9. PubMed ID: 25392275
[TBL] [Abstract][Full Text] [Related]
15. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
16. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
19. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
